Invesco
PRQR icon

Invesco’s ProQR Therapeutics PRQR Stock Holding History

Invesco’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$72.2K Buy
44,592
+19,245
+76% +$31.5K ﹤0.01% 3660
2025
Q4 		$51.2K Buy
+25,347
New +$59.2K ﹤0.01% 3703
2025
Q2 		– Sell
-18,084
Closed -$24.1K – 3844
2025
Q1 		$24.1K Buy
18,084
+6,197
+52% +$13.2K ﹤0.01% 3738
2024
Q4 		$31.5K Buy
+11,887
New +$37.7K ﹤0.01% 3724
2023
Q4 		– Sell
-20,822
Closed -$27.1K – 3883
2023
Q3 		$27.1K Buy
20,822
+1,700
+9% +$2.67K ﹤0.01% 3843
2023
Q2 		$31K Buy
+19,122
New +$37.3K ﹤0.01% 3846

Other funds holding PRQR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Invesco's PRQR Position: Q1 2026 in Review

Invesco increased its ProQR Therapeutics (PRQR) stake by 76% in Q1 2026, buying an estimated $31.5K and bringing the position to 44,592 shares worth $72.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3660.

Invesco first reported a position in PRQR in Q2 2023 and has held it in 6 quarters since. 69 funds tracked by Wall St. Rank hold PRQR as of Q1 2026.

  • Invesco held 44,592 shares of ProQR Therapeutics worth $72.2K as of Q1 2026.
  • Invesco bought 19,245 ProQR Therapeutics shares in Q1 2026, an estimated $31.5K.
  • ProQR Therapeutics made up ﹤0.01% of Invesco's portfolio in Q1 2026, its #3660 holding.
  • Invesco first reported a position in ProQR Therapeutics in Q2 2023 and has held it in 6 quarters since.
  • 69 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2026.

Based on Invesco's 13F filing for Q1 2026, filed 12 May 2026.